for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-CASI Pharma Submits Application To Conduct Study For Antibody Program

June 8 (Reuters) - CASI Pharmaceuticals Inc:

* CASI PHARMACEUTICALS ANNOUNCES SUBMISSION OF CLINICAL TRIAL APPLICATION (IND) TO CONDUCT PHASE 1 STUDY FOR ANTI-38 MONOCLONAL ANTIBODY PROGRAM

* CASI PHARMACEUTICALS INC - TARGETING STUDY INITIATION IN LATE 2020 OR EARLY 2021 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up